EU approves Elixir Medical's bioresorbable heart stent

05/16/2013 | (Boston)

Elixir Medical has earned the CE mark to market its DESolve Novolimus-eluting coronary stent in Europe. The bioresorbable stent, which is used to treat patients with coronary artery disease, degrades in the body in about a year, restoring the treated vessel to its normal de novo state. The company aims for a limited global release of the device later in the year.

View Full Article in: (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care